Develops rapid norovirus detection methods using recombinant antibodies, indicating effective screening options.
Norovirus (NoV) is a leading cause of acute gastroenteritis. We expressed GI.1 and GII.4 VP1 proteins and generated genotype-specific monoclonal antibodies (1C1 for GI.1; 7B5 and 10B8 for GII.4). Variable heavy chains and variable light chains were obtained, and full-length heavy/light chain vectors were constructed. Recombinant antibodies (rAbs) expressed in Expi293F and ExpiCHO cells showed an affinity comparable to that of ascite-derived antibodies. Using these rAbs, we developed a dual-antibody sandwich ELISA (DAS-ELISA) and a gold immunochromatographic strip (GICS). In oyster samples, DAS-ELISA limits of detection (LOD) were 3.23 ng/g (GI.1) and 2.16 ng/g (GII.4); visual limits of detection of GICS were 10 ng/g and 5 ng/g, respectively. Validation with 60 clinical samples showed good concordance with PCR, confirming the field-screening suitability. Molecular docking and molecular dynamics simulations identified 12 key interacting residues at the antibody-VP1 interface. Site-directed mutagenesis confirmed that mutating these CDR-localized residues reduced binding affinity by 60–90%, whereas mutation of a framework residue (GLN1) had only a minor effect. These findings provide structural insights into future antibody humanization or affinity maturation.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: